Psychiatr. praxi. 2021;22(3):138-142 | DOI: 10.36290/psy.2021.030

Treatment options for pharmacoresistant depression in routine clinical practice

prof. MUDr. Eva Češková, CSc.1, 2, 3
1 Psychiatrická klinika LF MU a FN Brno
2 KNP LF Ostravské univerzity
3 Oddělení psychiatrické FN Ostrava

Patients with first-episode patients differ from those with multi-episode and chronic schizophrenia in several important aspects. While treatment response the first-episode is better, the risk of relapse is higher. Poor medication adherence is a significant problem in early psychosis Both first- and second-generation antipsychotics are very effective in reducing symptoms, however, there are tolerability and retention in treatment advantages for the second-generation antipsychotics in first-episode psychosis. The early years after the first-episode a represent a critical period for further outcome and the best opportunity for achieving optimal outcomes.

Keywords: first‑episode schizophrenia, treatment response, retention in treatment, adherence, critical period.

Published: October 14, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Treatment options for pharmacoresistant depression in routine clinical practice. Psychiatr. praxi. 2021;22(3):138-142. doi: 10.36290/psy.2021.030.
Download citation

References

  1. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-549. Go to original source... Go to PubMed...
  2. Emsley R. New advances in pharmacotherapy for early psychosis. Early Interv Psychiatry 2009; 3 (Suppl 1): S8-12. Go to original source... Go to PubMed...
  3. Ortiz BB, Eden FD, de Souza AS, et al. New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage. Compr Psychiatry 2017; 73: 93-96. Go to original source... Go to PubMed...
  4. Dauvermann MR, Lee G, Dawson N. Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research. Br J Pharmacol. 2017; 174: 3136-3160. Go to original source... Go to PubMed...
  5. Zipursky RB, Agid O. Recovery, not progressive deterioration, should be the expectation in schizophrenia. World Psychiatry 2015; 14: 94-96. Go to original source... Go to PubMed...
  6. Birchwood, M, Todd, P, Jackson, C. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry 1998; 172 (suppl 33): 53-59. Go to original source... Go to PubMed...
  7. McGorry, PD. The recognition and optimal management of early psychosis: an evidence‑based reform. World Psychiatry 2002; 1: 76-83.
  8. Bleuler, M. The Schizophrenic Disorders: Long‑Term Patient and Family Studies. Yale University Press, 1978.
  9. Crumlish N, Whitty P, Clarke M, et al. Beyond the critical period: longitudinal study of 8-year outcome in first‑episode non‑affective psychosis. Br J Psychiatry 2009; 194: 18-24. Go to original source... Go to PubMed...
  10. Ceskova E, Prikryl R, Kasparek T. Outcome in males with first‑episode schizophrenia: 7-year follow‑up. World J Biol Psychiatry 2011; 12: 66-72. Go to original source... Go to PubMed...
  11. Bozzatello P, Bellino S, Rocca P. Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. Front Psychiatry 2019; 10: 67. Go to original source... Go to PubMed...
  12. Prikryl R, Ceskova E, Kasparek T, Kucerova H. Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia. J Psychiatr Res. 2006; 40: 141-146. Go to original source... Go to PubMed...
  13. Bucci P, Mucci A, van Rossum IW, et al. Persistent negative symptoms in recent‑onset psychosis: Relationship to treatment response and psychosocial functioning. Eur Neuropsychopharmacol. 2020; 34: 76-86. Go to original source... Go to PubMed...
  14. Fraguas D, Díaz‑Caneja CM, Pina‑Camacho L, et al. The role of depression in the prediction of a "late" remission in first‑episode psychosis: An analysis of the OPTiMiSE study. Schizophr Res. 2021; 231: 100-107. Go to original source... Go to PubMed...
  15. Kahn RS, Winter van Rossum I, Leucht S, et al.; OPTiMiSE study group. Amisulpride and olanzapine followed by open‑label treatment with clozapine in first‑episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three‑phase switching study. Lancet Psychiatry 2018; 5: 797-807. Go to original source... Go to PubMed...
  16. Dazzan P, Arango C, Fleischacker W, et al. Magnetic resonance imaging and the prediction of outcome in first‑episode schizophrenia: a review of current evidence and directions for future research. Schizophr Bull. 2015; 41: 574-583. Go to original source... Go to PubMed...
  17. Egerton A, Broberg BV, Van Haren N, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H‑MRS study (OPTiMiSE). Mol Psychiatry 2018; 23: 2145-2155. Go to original source... Go to PubMed...
  18. Troudet R, Ali WBH, Bacq‑Daian D, et al., OPTiMiSE study group; Rujescu D, McGuire P, Kahn RS, Deleuze JF, Leboyer M, Jamain S. Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses. Neuropsychopharmacology 2020; 45: 1637-1644. Go to original source... Go to PubMed...
  19. Martinuzzi E, Barbosa S, Daoudlarian D, et al.; OPTiMiSE Study Group. Stratification and prediction of remission in first‑episode psychosis patients: the OPTiMiSE cohort study. Transl Psychiatry 201; 9: 20. Go to original source... Go to PubMed...
  20. Lieberman JA, Tollefson G, Tohen M, et al.; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first‑episode psychosis: a randomized, double‑blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396-1404. Go to original source... Go to PubMed...
  21. Möller HJ, Riedel M, Jäger M, et al. Short‑term treatment with risperidone or haloperidol in first‑episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol. 2008;11: 985-997. Go to original source... Go to PubMed...
  22. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first‑episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085-1097. Go to original source... Go to PubMed...
  23. Gómez‑Revuelta M, Pelayo‑Terán JM, Juncal‑Ruiz M, et al. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow‑Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. Int J Neuropsychopharmacol. 2020; 23: 217-229. Go to original source... Go to PubMed...
  24. Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long‑term effectiveness of oral second‑generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‑analysis of direct head‑to‑head comparisons. World Psychiatry 2019; 18: 208-224. Go to original source... Go to PubMed...
  25. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first‑episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long‑acting injection. Int Clin Psychopharmacol. 2008; 23: 325-231. Go to original source... Go to PubMed...
  26. Salgueiro, M, Segarra, R. Long‑acting injectable second‑generation antipsychotics in first‑episode psychosis a narrative review. Int Clin Psychopharmacol. 2019; 34: 51-56. Go to original source... Go to PubMed...
  27. Agid O, Arenovich T, Sajeev G, et al. An algorithm‑based approach to first‑episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72 : 1439-1444. Go to original source... Go to PubMed...
  28. Earley W, Guo H, Daniel D, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res. 2019; 204: 282-288. Go to original source... Go to PubMed...
  29. Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019; 15: 1525-1535. Go to original source... Go to PubMed...
  30. Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short‑term placebo- and active‑controlled study followed by a 6-month double‑blind extension. Eur Neuropsychopharmacol. 2013; 23: 1373-1382. Go to original source... Go to PubMed...
  31. Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019; 29: 971-985. Go to original source... Go to PubMed...
  32. Ceskova E. Pharmacological strategies for the management of comorbid depression and schizophrenia. Expert Opin Pharmacother. 2020;21: 459-465. Go to original source... Go to PubMed...
  33. Caraci F, Leggio GM, Salomone S, Drago F. New drugs in psychiatry: focus on new pharmacological targets. F1000Res. 2017; 6: 397. Go to original source... Go to PubMed...
  34. Moreno C, Parellada M, MacDowell KS, et al.; From the FLAMM‑PEPs study, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). Differences in the regulation of inflammatory pathways in adolescent- and adult‑onset first‑episode psychosis. Eur Child Adolesc Psychiatry 2019; 28: 1395-1405. Go to original source... Go to PubMed...
  35. Fond G, Lançon C, Korchia T, Auquier P, Boyer L. The Role of Inflammation in the Treatment of Schizophrenia. Front Psychiatry 2020; 11: 160. Go to original source... Go to PubMed...
  36. Cha HY, Yang SJ. Anti‑Inflammatory Diets and Schizophrenia. Clin Nutr Res. 2020; 9: 241-257. Go to original source... Go to PubMed...
  37. Stubbs B, Vancampfort D, Hallgren M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta‑review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry 2018; 54: 124-144. Go to original source... Go to PubMed...
  38. Plana‑Ripoll O, Weye N, Momen NC, et al. Changes Over Time in the Differential Mortality Gap in Individuals with Mental Disorders. JAMA Psychiatry 2020; 77: 648-650. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.